418 related articles for article (PubMed ID: 37641443)
1. Therapeutic targeting of ALS pathways: Refocusing an incomplete picture.
Maragakis NJ; de Carvalho M; Weiss MD
Ann Clin Transl Neurol; 2023 Nov; 10(11):1948-1971. PubMed ID: 37641443
[TBL] [Abstract][Full Text] [Related]
2. A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies.
DeLoach A; Cozart M; Kiaei A; Kiaei M
Expert Opin Drug Discov; 2015 Oct; 10(10):1099-118. PubMed ID: 26307158
[TBL] [Abstract][Full Text] [Related]
3. [Biomarkers of amyotrophic lateral sclerosis].
Khabibrakhmanov AN; Mukhamedyarov MA; Bogdanov EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(5):30-35. PubMed ID: 35611897
[TBL] [Abstract][Full Text] [Related]
4. TAR DNA-binding protein of 43 kDa (TDP-43) and amyotrophic lateral sclerosis (ALS): a promising therapeutic target.
Ojaimi YA; Dangoumau A; Alarcan H; Hergesheimer R; Vourc'h P; Corcia P; Lanznaster D; Blasco H
Expert Opin Ther Targets; 2022 Jun; 26(6):575-592. PubMed ID: 35652285
[TBL] [Abstract][Full Text] [Related]
5. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Liu Y; Deng W
Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
[TBL] [Abstract][Full Text] [Related]
6. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation.
Mead RJ; Shan N; Reiser HJ; Marshall F; Shaw PJ
Nat Rev Drug Discov; 2023 Mar; 22(3):185-212. PubMed ID: 36543887
[TBL] [Abstract][Full Text] [Related]
7. Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis.
Thompson AG; Oeckl P; Feneberg E; Bowser R; Otto M; Fischer R; Kessler B; Turner MR
Expert Rev Proteomics; 2021 Nov; 18(11):977-994. PubMed ID: 34758687
[TBL] [Abstract][Full Text] [Related]
8. Neural and glial progenitor transplantation as a neuroprotective strategy for Amyotrophic Lateral Sclerosis (ALS).
Haidet-Phillips AM; Maragakis NJ
Brain Res; 2015 Dec; 1628(Pt B):343-350. PubMed ID: 26187754
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory checkpoints in amyotrophic lateral sclerosis: From biomarkers to therapeutic targets.
Jiang Z; Wang Z; Wei X; Yu XF
Front Immunol; 2022; 13():1059994. PubMed ID: 36618399
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic progress in amyotrophic lateral sclerosis-beginning to learning.
Kumar V; Islam A; Hassan MI; Ahmad F
Eur J Med Chem; 2016 Oct; 121():903-917. PubMed ID: 27372371
[TBL] [Abstract][Full Text] [Related]
11. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
[TBL] [Abstract][Full Text] [Related]
12. Senolytics: A Novel Strategy for Neuroprotection in ALS?
Maximova A; Werry EL; Kassiou M
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769512
[TBL] [Abstract][Full Text] [Related]
13. Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study.
Deeb O; Nabulsi M
Curr Top Med Chem; 2020; 20(26):2391-2403. PubMed ID: 32972341
[TBL] [Abstract][Full Text] [Related]
14. Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis.
Gladman M; Cudkowicz M; Zinman L
Curr Opin Neurol; 2012 Dec; 25(6):735-42. PubMed ID: 23160423
[TBL] [Abstract][Full Text] [Related]
15. High content analysis in amyotrophic lateral sclerosis.
Rinaldi F; Motti D; Ferraiuolo L; Kaspar BK
Mol Cell Neurosci; 2017 Apr; 80():180-191. PubMed ID: 27965018
[TBL] [Abstract][Full Text] [Related]
16. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS.
Goyal NA; Berry JD; Windebank A; Staff NP; Maragakis NJ; van den Berg LH; Genge A; Miller R; Baloh RH; Kern R; Gothelf Y; Lebovits C; Cudkowicz M
Muscle Nerve; 2020 Aug; 62(2):156-166. PubMed ID: 31899540
[TBL] [Abstract][Full Text] [Related]
17. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol.
Kalmar B; Lu CH; Greensmith L
Pharmacol Ther; 2014 Jan; 141(1):40-54. PubMed ID: 23978556
[TBL] [Abstract][Full Text] [Related]
18. Where and Why Modeling Amyotrophic Lateral Sclerosis.
Liguori F; Amadio S; Volonté C
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921446
[TBL] [Abstract][Full Text] [Related]
19. Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis.
Staats KA; Borchelt DR; Tansey MG; Wymer J
Mol Neurodegener; 2022 Jan; 17(1):11. PubMed ID: 35073950
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
